Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Jiangsu Hengrui Pharmaceuticals has signed a major licensing agreement, granting GlaxoSmithKline (GSK) worldwide rights to its HRS-9821 drug and 11 additional programs for an upfront payment of $500 million. If all development and sales milestones are reached, Hengrui could receive as much as $12 billion in total.
HRS-9821 is currently in development for chronic obstructive pulmonary disease (COPD), while the other assets span early-stage projects in oncology, respiratory, immunology, and inflammation. News of the deal sent Hengrui’s Shanghai-listed shares up 6.6% and its Hong Kong shares soaring 8.5%, far outperforming local indices.
This blockbuster partnership highlights the increasing global footprint of Chinese pharmaceutical innovation and brings Hengrui one step closer to international markets.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition
-
BASF’s Zhanjiang Integrated Site Commissions New Neopentyl Glycol (NPG) Unit
-
BASF and IFF Collaborate to Accelerate Innovation in Enzymes and Polymers
-
When Light Falls on Metal: The Industrial Romance of Xiaomi × BASF
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
LBB Specialties to Distribute Imerys' Mineral Ingredients in North America
-
Evonik to Close Two German Plants, Further Cutting Europe’s High-Purity Silicon Tetrachloride Capacity
-
Evonik Reportedly Rejects BASF’s €10.3 Billion Takeover Bid as Too Low
-
OCI Exits TDI Business and Joins South Korean Semiconductor Materials Cluster on the Same Day
Recommend Reading
-
![Wanhua Chemical Expands TPU Production by 200,000 Tons with RMB 287 Million Investment]()
Wanhua Chemical Expands TPU Production by 200,000 Tons with RMB 287 Million Investment
-
![Aster Opens Singapore’s Storage and Marine Network to Third Parties]()
Aster Opens Singapore’s Storage and Marine Network to Third Parties
-
![Braskem Weighs Out-of-Court Restructuring as $10 Billion Debt Burden Deepens Petrochemical Crisis]()
Braskem Weighs Out-of-Court Restructuring as $10 Billion Debt Burden Deepens Petrochemical Crisis
-
![Ancora Offers Up to $1.2 Billion for H.B. Fuller Building Adhesives Business]()
Ancora Offers Up to $1.2 Billion for H.B. Fuller Building Adhesives Business
-
![Two Major Dye Giants Hike Prices Consecutively: Longsheng Raises Prices by Up to RMB 10,000/Ton, Yabang Increases Some Products by RMB 60,000/Ton]()
Two Major Dye Giants Hike Prices Consecutively: Longsheng Raises Prices by Up to RMB 10,000/Ton, Yabang Increases Some Products by RMB 60,000/Ton
-
![Business Society September 29, 2026 Maleic Anhydride Trend Analysis: Volatility]()
Business Society September 29, 2026 Maleic Anhydride Trend Analysis: Volatility
-
![Cost Supply Supports Wide Market Fluctuations; Toluene Prices in China Rise 14.92% in September]()
Cost Supply Supports Wide Market Fluctuations; Toluene Prices in China Rise 14.92% in September
-
![Business Society DOP Trend Analysis for September 30, 2026: Strong Rebound with a Bullish Bias]()
Business Society DOP Trend Analysis for September 30, 2026: Strong Rebound with a Bullish Bias
-
![Business Society September 30, 2026 Hydrofluoric Acid Trend Analysis: Sideways Fluctuations]()
Business Society September 30, 2026 Hydrofluoric Acid Trend Analysis: Sideways Fluctuations
-
![Business Society September 30, 2026 Styrene Trend Analysis: Volatile with a Slight Upward Bias]()
Business Society September 30, 2026 Styrene Trend Analysis: Volatile with a Slight Upward Bias
